IGF-1LR3 1 MG

IGF-1 LR3 is a modified synthetic polypeptide analogue of IGF-1 supplied for controlled laboratory, analytical, and scientific research.

The LR3 designation refers to structural modifications that distinguish it from native IGF-1, including an extended N-terminal peptide segment and substitution of arginine at the third position of the IGF-1 sequence. These modifications produce a research material with a molecular identity that should be documented independently from native IGF-1.

Because commercial IGF-1 LR3 materials can differ in expression system, terminal state, salt form, purity specification, and analytical representation, the applicable Certificate of Analysis should be treated as the controlling source for final molecular specifications.

Research Applications

IGF-1 LR3 may be examined in controlled non-clinical research involving:

• Polypeptide identity and characterization
• Ligand-receptor interaction studies
• Molecular signaling research
• Structure-function analysis
• Comparative protein and peptide research
• Binding studies
• Stability assessment
• Non-clinical biochemical and cellular models

Any experimental findings should remain limited to the applicable research system and should not be interpreted as evidence of growth-related benefit, muscle-building benefit, performance enhancement, therapeutic effectiveness, or suitability for human use.

Structural Information

IGF-1 LR3 is an engineered analogue of IGF-1 rather than a simple unmodified peptide.

Key structural characteristics include:

• An 83-residue polypeptide structure
• An extended N-terminal sequence
• An Arg substitution at position 3
• Structural differences from native 70-residue IGF-1

These modifications form part of its complete molecular identity and should be considered during sequence verification and analytical characterization.

Analytical Identification

Relevant analytical characterization may include:

• Polypeptide identity confirmation
• Sequence verification
• Molecular mass assessment
• Chromatographic purity testing
• Intact-mass analysis
• Structural characterization
• Lot-specific quality testing

Because IGF-1 LR3 is a modified polypeptide, analytical identity should be based on the exact construct supplied rather than generalized IGF-1 specifications.

Specifications & Documentation

Lot-specific documentation should be reviewed for:

• Exact IGF-1 LR3 construct
• Amino-acid sequence
• Polypeptide length
• Molecular mass
• Expression or synthesis method
• Terminal state
• Salt or counter-ion form
• Purity specification
• Analytical testing
• Lot or batch identification
• Certificate of Analysis
• Storage requirements

Authenticated product-specific documentation should take precedence over generalized reference values.

Storage & Handling

Store according to the conditions specified on the product label and Certificate of Analysis. Protect the material from environmental conditions that could compromise polypeptide integrity.

Handling should follow established laboratory procedures appropriate for research polypeptides.

Research Use Only

IGF-1 LR3 is supplied exclusively for laboratory research, analytical testing, and scientific reference purposes.

Disclaimer

For research use only. Not for human or veterinary use. Not intended for consumption, administration, muscle-building use, performance enhancement, growth-related use, diagnosis, treatment, mitigation, cure, or prevention of any disease. No therapeutic, anabolic, growth-related, performance-related, medical, or clinical claims are made or implied. Product information is supplied solely for scientific identification, documentation, and research reference.